The Global NASH Biomarker Market Calculated to Gain $3700.0 Million in Revenue by 2028

According to Triton’s report, the global non-alcoholic steatohepatitis (NASH) biomarker market, which garnered $772.4 million in 2020, is projected to observe growth at 21.28% of CAGR by 2028.

A recent study by Triton Market Research titled ‘Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market’ comprises the Global Analysis and Forecasts by Industry Verticals (Hospital, Academic Research Key, Pharma & CRO Industry, Diagnostic Lab), Type (Oxidative stress Biomarker, Apoptosis Biomarker, Hepatic fibrosis Biomarker, Serum Biomarker, Other Types), and by Geography (Latin America, Europe, Asia-Pacific, Middle East and Africa, North America).

Request Free Sample of the Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market Report @ https://www.tritonmarketresearch.com/reports/non-alcoholic-steatohepatitis-biomarker-market#request-free-sample

Triton’s report estimates the global non-alcoholic steatohepatitis (NASH) biomarker market to develop at a CAGR of 21.28% through the years 2021-2028. It is further predicted to witness revenue growth at $3700.0 million by 2028.

NASH, a severe form of non-alcoholic fatty liver disease, can further lead to the development of chronic disorders like cirrhosis. A non-alcoholic steatohepatitis biomarker finds applications in hospitals, CROs, and pharmaceuticals.

The key drivers promoting the growth of the non-steatohepatitis (NASH) biomarker market include the rising occurrence of NASH and increasing cases of metabolic comorbidities. In recent years, the incidence rate of obesity has surged, affecting a large number of people globally. This increases the risk of developing NASH, growing the need for better medical services. Further, non-alcoholic fatty liver disease is among the leading causes of liver damage, resulting in the emergence of NASH. Hence, such factors increasing the prevalence of NASH are likely to support the growth of the NASH biomarker market over the upcoming years.

However, the side effects of NASH therapeutics, coupled with the absence of specialized diagnostics tests to treat non-alcoholic fatty liver disease, are obstructing the overall progress of the NASH biomarker market.

The non-alcoholic steatohepatitis biomarker market is divided into industry verticals and type. In terms of industry verticals, the market is segmented into hospital, academic research key, pharma & CRO industry, and diagnostic labs. The type segment is branched into oxidative stress biomarker, apoptosis biomarker, hepatic fibrosis biomarker, serum biomarker, and other types.

The Asia-Pacific is estimated to become the fastest-growing in the NASH biomarker market over the projected period. The region’s growth can be attributed to the improvement in healthcare infrastructure, surge in the prevalence of NASH, and advancement in economic conditions. Additionally, the increase in diagnosis rate is also anticipated to support the growth of the studied market across the region. Above, the growing healthcare awareness in countries like India and China is expected to boost the non-alcoholic steatohepatitis market on a growth path.

Allergan, Gilead Sciences Inc, Viking Therapeutics, Pfizer Inc, Novo Nordisk, Novartis AG, Genfit SA, Madrigal Pharmaceuticals, AstraZeneca, Merck & Co, Bristol Myers Squibb Company, Zydus Cadila, and Siemens Healthineers are enterprises thriving in the given market.

Purchase this Report @ https://www.tritonmarketresearch.com/reports/non-alcoholic-steatohepatitis-biomarker-market#purchase-option

Question & Answer: Non-Alcoholic Steatohepatitis (NASH) Biomarker Market

Question 1: What key drivers are promoting the growth of the non-steatohepatitis (NASH) biomarker market?

Answer: The key drivers promoting the growth of the non-steatohepatitis (NASH) biomarker market include the rising occurrence of NASH and increasing cases of metabolic comorbidities.
In recent years, the incidence rate of obesity has surged, affecting a large number of people globally. This increases the risk of developing NASH, growing the need for better medical services. Further, non-alcoholic fatty liver disease is among the leading causes of liver damage, resulting in the emergence of NASH. Hence, such factors increasing the prevalence of NASH are likely to support the growth of the NASH biomarker market over the upcoming years.

Question 2: What factors are obstructing the overall progress of the NASH biomarker market?

Answer: The side effects of NASH therapeutics, coupled with the absence of specialized diagnostics tests to treat non-alcoholic fatty liver disease, are obstructing the overall progress of the NASH biomarker market.

Question 3: Which region is estimated to become the fastest-growing in the NASH biomarker market?

Answer: The Asia-Pacific is estimated to become the fastest-growing in the NASH biomarker market over the projected period. The region’s growth can be attributed to the improvement in healthcare infrastructure, surge in the prevalence of NASH, and advancement in economic conditions. Additionally, the increase in diagnosis rate is also anticipated to support the growth of the studied market across the region. Above, the growing healthcare awareness in countries like India and China is expected to boost the non-alcoholic steatohepatitis market on a growth path.

Question 4: Which are the enterprises thriving in the NASH biomarker market?

Answer: Allergan, Gilead Sciences Inc, Viking Therapeutics, Pfizer Inc, Novo Nordisk, Novartis AG, Genfit SA, Madrigal Pharmaceuticals, AstraZeneca, Merck & Co, Bristol Myers Squibb Company, Zydus Cadila, and Siemens Healthineers are enterprises thriving in the given market.

Related Report:

Global Bariatric Surgery Market
The global bariatric surgery market is likely to display growth in its revenue during 2019-2028 at a CAGR of 9.41%. It is predicted to acquire revenue of $4913.1 million by 2028.

Bariatric surgery or weight loss surgery is usually the last option by patients who have failed to lose weight through other methods. It is among the well-known treatments for obesity.

Factors such as the growing occurrence of diabetes and cardiac disease, and rising obesity rates, are supporting the development of the bariatric surgery market globally. Besides, the technological advancements are creating new opportunities for the market to leverage to attain its expected growth.

However, the high cost of bariatric surgeries, along with a lack of awareness among patients, impede the progression of the studied market over the forecast period.

Triton Market Research
196, wards wharf approach
London E16 2EQ
Phone: +44 7441 911839
Email: sales@tritonmarketresearch.com
Website: https://www.tritonmarketresearch.com/

We are a leading market research company with offices in the UK, providing the best online market research and data search reports to our clients.

This release was published on openPR.